Novo Nordisk (NOVOB DC) announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus, building on continued efforts to expand access

• New, lower list price of USD 675/month across Wegovy, Ozempic, and Rybelsus, effective January 1st, 2027.
• These changes in list price do not have an impact on direct-to-patient, self-pay prices
• Decision applies to all doses of these medicines.

Novo Nordisk's announcement of a significant reduction in the US list price for Wegovy, Ozempic, and Rybelsus signals the company's continued commitment to enhancing patient access. While this move does not affect direct-to-patient prices, it may pressure market dynamics and competitor pricing strategies ahead of the effective date. Traders should monitor how this impacts Novo Nordisk's share price and broader market sentiment regarding the pharmaceutical sector.